Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
November 14, 2024 16:05 ET
|
Omega Therapeutics
Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring...
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
October 15, 2024 08:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
September 17, 2024 07:00 ET
|
Omega Therapeutics
Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care agents...
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
August 14, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic...
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 06, 2024 07:00 ET
|
Omega Therapeutics
Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024Reinforced diverse...
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
June 24, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
May 30, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
May 29, 2024 07:00 ET
|
Omega Therapeutics
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
May 08, 2024 07:00 ET
|
Omega Therapeutics
Programmable epigenomic mRNA candidates enabled durable and robust upregulation of gene expression across a diverse set of gene types and regulatory mechanismsAdditional OMEGA platform capabilities...
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 06, 2024 07:00 ET
|
Omega Therapeutics
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data...